Synopsis
0
USDMF
0
KDMF
0
VMF
0
FDA Orange Book
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
70
PharmaCompass offers a list of Clobetasone Butyrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Clobetasone Butyrate manufacturer or Clobetasone Butyrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Clobetasone Butyrate manufacturer or Clobetasone Butyrate supplier.
PharmaCompass also assists you with knowing the Clobetasone Butyrate API Price utilized in the formulation of products. Clobetasone Butyrate API Price is not always fixed or binding as the Clobetasone Butyrate Price is obtained through a variety of data sources. The Clobetasone Butyrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Clobetasone 17-Butyrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Clobetasone 17-Butyrate, including repackagers and relabelers. The FDA regulates Clobetasone 17-Butyrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Clobetasone 17-Butyrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Clobetasone 17-Butyrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Clobetasone 17-Butyrate supplier is an individual or a company that provides Clobetasone 17-Butyrate active pharmaceutical ingredient (API) or Clobetasone 17-Butyrate finished formulations upon request. The Clobetasone 17-Butyrate suppliers may include Clobetasone 17-Butyrate API manufacturers, exporters, distributors and traders.
click here to find a list of Clobetasone 17-Butyrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Clobetasone 17-Butyrate Drug Master File in Japan (Clobetasone 17-Butyrate JDMF) empowers Clobetasone 17-Butyrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Clobetasone 17-Butyrate JDMF during the approval evaluation for pharmaceutical products. At the time of Clobetasone 17-Butyrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Clobetasone 17-Butyrate suppliers with JDMF on PharmaCompass.
A Clobetasone 17-Butyrate CEP of the European Pharmacopoeia monograph is often referred to as a Clobetasone 17-Butyrate Certificate of Suitability (COS). The purpose of a Clobetasone 17-Butyrate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Clobetasone 17-Butyrate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Clobetasone 17-Butyrate to their clients by showing that a Clobetasone 17-Butyrate CEP has been issued for it. The manufacturer submits a Clobetasone 17-Butyrate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Clobetasone 17-Butyrate CEP holder for the record. Additionally, the data presented in the Clobetasone 17-Butyrate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Clobetasone 17-Butyrate DMF.
A Clobetasone 17-Butyrate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Clobetasone 17-Butyrate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Clobetasone 17-Butyrate suppliers with CEP (COS) on PharmaCompass.
A Clobetasone 17-Butyrate written confirmation (Clobetasone 17-Butyrate WC) is an official document issued by a regulatory agency to a Clobetasone 17-Butyrate manufacturer, verifying that the manufacturing facility of a Clobetasone 17-Butyrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Clobetasone 17-Butyrate APIs or Clobetasone 17-Butyrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Clobetasone 17-Butyrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Clobetasone 17-Butyrate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Clobetasone 17-Butyrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Clobetasone 17-Butyrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Clobetasone 17-Butyrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Clobetasone 17-Butyrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Clobetasone 17-Butyrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Clobetasone 17-Butyrate suppliers with NDC on PharmaCompass.
Clobetasone 17-Butyrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Clobetasone 17-Butyrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Clobetasone 17-Butyrate GMP manufacturer or Clobetasone 17-Butyrate GMP API supplier for your needs.
A Clobetasone 17-Butyrate CoA (Certificate of Analysis) is a formal document that attests to Clobetasone 17-Butyrate's compliance with Clobetasone 17-Butyrate specifications and serves as a tool for batch-level quality control.
Clobetasone 17-Butyrate CoA mostly includes findings from lab analyses of a specific batch. For each Clobetasone 17-Butyrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Clobetasone 17-Butyrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Clobetasone 17-Butyrate EP), Clobetasone 17-Butyrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Clobetasone 17-Butyrate USP).
